GET DAILY SIGNALSAmylyx Pharmaceuticals (AMLX) Q3 Results: Cash Position Bolsters Path to 2027 Avexitide Launch
Key Takeaways
- Amylyx reported a net loss of $45.5 million, or $0.38 per share, for the third quarter of 2026, roughly in line with the consensus estimate of a $0.38 loss per share.
- The company's cash and cash equivalents jumped to $768 million, up from $251 million at the end of the second quarter, after a $545 million oversubscribed equity offering.
- Total operating expenses rose 38% year over year to $49.7 million, driven by spending on the pivotal LUCIDITY trial and pre-commercialization activities.
- Management is advancing avexitide, its lead drug candidate for post-bariatric hypoglycemia (PBH, a condition causing dangerously low blood sugar after weight-loss surgery), toward a potential launch in 2027.
- You can get more details on this ticker's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
Earnings Context and Why It Matters
Amylyx Pharmaceuticals is a clinical-stage biotech that has shifted its focus to avexitide, a potential first approved treatment for PBH. This earnings report matters less for traditional revenue metrics and more for what it signals about the company's transition from clinical development to commercialization. Following positive results from the phase III LUCIDITY trial, Amylyx is now investing heavily in a launch-readiness roadmap while preparing a New Drug Application (NDA), a formal request for regulatory approval. For investors, the key questions center on cash runway, spending discipline, and execution toward a potential 2027 launch — all of which were in focus this quarter. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the quarter ended September 30, 2026, Amylyx reported a net loss of $45.5 million, or $0.38 per share, compared with a net loss of $34.4 million, or $0.37 per share, in the same period a year earlier. The result was essentially in line with the Wall Street consensus estimate of a $0.38 loss per share.
Total operating expenses climbed 38% year over year to $49.7 million. Research and development (R&D) expenses rose to $28.4 million from $19.9 million, primarily reflecting spending tied to the LUCIDITY clinical trial and avexitide-related work, partially offset by reduced spending on AMX0035. Selling, general, and administrative (SG&A) expenses increased to $21.3 million from $16.2 million, driven by pre-commercialization hiring and related personnel costs. Non-cash stock-based compensation was $10.4 million, up from $7.1 million a year earlier.
The standout financial item was the balance sheet: Amylyx ended the quarter with $768 million in cash and cash equivalents, bolstered by $545 million in net proceeds from a recent equity offering. The company reported no product revenue during the period.
Market Reaction and Investor Sentiment
Heading into the report, investor attention was less on the headline loss and more on Amylyx's capital position and its path toward a potential 2027 launch of avexitide. The company's sharply expanded cash balance following its oversubscribed offering has been a central theme, giving management a stronger runway to fund launch preparation from a position of financial strength. In prior quarters, the stock had reacted sensitively to expense growth and EPS shortfalls, but the third-quarter results — including an in-line loss and a much larger cash cushion — reinforce a narrative of execution rather than deterioration. Sentiment remains tied to upcoming regulatory milestones and the broader PBH market opportunity rather than near-term profitability.
Forward Outlook and Key Factors to Monitor
The most important near-term catalyst for Amylyx is the progression of avexitide through the regulatory process. Management has indicated it is focused on NDA preparation, with the goal of potentially commercializing the first approved therapy for PBH in 2027. Amylyx estimates there are roughly 160,000 people living with PBH in the United States, a figure it says is supported by independent claims analysis.
Investors should also watch spending trends. The company is scaling its commercial organization across marketing, market access, patient services, and operations, which will continue to pressure operating expenses in coming quarters. How quickly Amylyx invests versus how it preserves its enlarged cash balance will be a key balance to monitor.
Beyond avexitide, the company is advancing AMX0318, a long-acting GLP-1 (glucagon-like peptide-1) receptor antagonist, in preclinical studies. While early stage, this program could broaden the pipeline over time. Upcoming investor events, including a presentation at ObesityWeek, may offer additional color on the PBH market and the avexitide data. As always, regulatory decisions and clinical updates — rather than quarterly losses — are likely to be the primary drivers of the stock.
Exploring AI Tools for Biotech Analysis
In my view, tools like Tickeron’s AI Screener can help investors quickly compare companies like AMLX against peers on fundamentals, technical signals, and industry trends. I find it useful for spotting patterns in clinical-stage names without manually sifting through dozens of filings. This approach keeps research efficient when tracking cash burn and pipeline milestones.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AMLX's RSI Oscillator recovers from oversold territory
The RSI Oscillator for AMLX moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 27 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on AMLX as a result. In 63 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for AMLX just turned positive on October 20, 2026. Looking at past instances where AMLX's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.
Following a +4.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMLX advanced for three days, in 233 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 55 cases where AMLX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
AMLX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AMLX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
AMLX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AMLX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. AMLX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.429) is normal, around the industry mean (7.659). P/E Ratio (-20.851) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (3.627) is also within normal values, averaging (181.047).
The Tickeron Profit vs. Risk Rating rating for this company is 69 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement